ESMO 2023 | Advanced ctDNA assay for pre-op lung cancer stratification

Federica Di Nicolantonio, PhD, University of Torino, Turin, Italy, discusses the breakthroughs in ctDNA detection using the NeXT Personal platform. The ultra-sensitive approach achieved consistent detection thresholds within 1-3 parts per million with over 99.95% specificity. In a cohort of early-stage lung cancer patients, ctDNA was pre-operatively detected in 81% of lung adenocarcinomas (LUADs), correlating with overall and relapse-free survival. Notably, even low ctDNA levels below 80 PPM, the 95% limit of detection, indicated reduced overall survival. The NeXT Personal platform shows promise for advanced stratification and guiding adjuvant therapy in early-stage ctDNA-positive disease. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.